Recent studies have identified specific immunoglobulin (Ig) G4 antibodies against the paranodal proteins neurofascin 155 and contactin 1 in subgroups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These patients present with distinct clinical phenotypes and poor response to first-line therapy with intravenous Ig. Detection of these antibodies in patients with CIDP has diagnostic, prognostic, and therapeutic implications. This review summarises the current knowledge on clinical characteristics, pathogenesis and treatment of these patients.
|Bidragets oversatte titel||Antibodies in patients with chronic inflammatory demyelinating polyneuropathy|
|Tidsskrift||Ugeskrift for Læger|
|Status||Udgivet - aug. 2019|